Author

Yuxiang Zhang

Scripps Research InstituteORCID 0000-0002-5110-5684Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Yuxiang Zhang1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Michael A. ErbiD· 2 shared Anissa R. Ramos· 1 shared Benjamin F. CravattiD· 1 shared Charles O. RockiD· 1 shared Chitra SubramanianiD· 1 shared Christopher J. OttiD· 1 shared Eric M. BilottaiD· 1 shared Joshua N. AsiabaniD· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Michael A. ErbORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintFeb 26, 2026

Dissecting FOXA1 pioneering function by acute pharmacological degradation

Lauren M. Hargis, Paige A. Barta, Yuxiang Zhang…·Michael A. Erb

This study uses a chemical degradation system to show FOXA1 opens chromatin exclusively at its binding sites, activating or repressing transcription based on the chromatin environment.

DOI 10.64898/2026.02.25.707765

𝕏 PostBluesky

Molecular BiologyNature Chemical BiologyPeer-reviewedMay 1, 2023

Metabolic adaptations underpin resistance to histone acetyltransferase inhibition

Timothy R. Bishop, Chitra Subramanian, Eric M. Bilotta…·Michael A. Erb

This study identifies CoA metabolism dysregulation as a mechanism of resistance to HAT inhibitors in AML, revealing a potential class-wide vulnerability for anti-cancer therapies targeting HATs.

39 citations

humanbulk RNA-seq

𝕏 PostBluesky